Metabolic effects of an entero-omentectomy in mildly obese type 2 diabetes mellitus patients after three years

Clinics

Volumn 66, Issue 7, 2011, Pages 1227-1233

  Milleo, Fábio Quirilo ^a   Campos, Antonio Carlos Ligocki ^b   Santoro, Sérgio ^c   Lacombe, Arnaldo ^c   Santo, Marco Aurélio ^d   Vicari, Marcelo Ricardo ^e   Nogaroto, Viviane ^e   Artoni, Roberto Ferreira ^e  

^a Hospital Vicentino da Sociedade Beneficente São Camilo   (Brazil)

^b FEDERAL UNIVERSITY OF PARANÁ   (Brazil)

^c HOSPITAL ISRAELITA ALBERT EINSTEIN   (Brazil)

^d UNIVERSITY OF SÃO PAULO   (Brazil)

^e STATE UNIVERSITY OF PONTA GROSSA   (Brazil)

Author keywords

Enterectomy; GLP 1; Metabolic surgery; Omentectomy; PYY; Type 2 diabetes mellitus

Indexed keywords

GLUCAGON LIKE PEPTIDE 1; PEPTIDE YY;

ADULT; ARTICLE; BODY MASS; FEMALE; HUMAN; JEJUNUM; MALE; METABOLIC SYNDROME X; METABOLISM; MIDDLE AGED; NON INSULIN DEPENDENT DIABETES MELLITUS; NUTRITIONAL STATUS; OMENTUM; PHYSIOLOGY; POSTOPERATIVE PERIOD; SECRETION; TIME; TREATMENT OUTCOME;

ADULT; BODY MASS INDEX; DIABETES MELLITUS, TYPE 2; FEMALE; GLUCAGON-LIKE PEPTIDE 1; HUMANS; JEJUNUM; MALE; METABOLIC SYNDROME X; MIDDLE AGED; NUTRITIONAL STATUS; OMENTUM; PEPTIDE YY; POSTOPERATIVE PERIOD; TIME FACTORS; TREATMENT OUTCOME;

EID: 80052177904     PISSN: 18075932     EISSN: None     Source Type: Journal    
DOI: 10.1590/S1807-59322011000700018     Document Type: Article

References (37)

1. Santoro S, Milleo FQ, Malzoni CE, Klajner S, Borges PC, Santo MA, et al. Enterohormonal changes after Digestive Adaptation: Five-year results of a surgical proposal to treat obesity and associated diseases. Obes Surg. 2008;18:17-26, doi: 10.1007/s11695-007-9371-0.
2. English PJ, Ghatei MA, Malik IA, Bloom SR, Wilding JP. Food fails to suppress ghrelin levels in obese humans. J Clin Endocrinol Metab. 2002;87:2984, doi: 10.1210/jc.87.6.2984.
3. Gustavo PSM, João LMCA, Carlos GN, Cora LCBM, Elaine CV, Perseu SC. Glucose homeostasis and weight loss in morbidly obese patients undergoing banded sleev gastrectomy: a prospective clinical study. Clinics. 2009;64:1093-8.
4. Barzilai N, She L, Liu BQ, Vuguin P, Cohen P, Wang J, et al. Surgical removal of visceral fat reverses hepatic insulin resistance. Diabetes. 1999;48:94-8, doi: 10.2337/diabetes.48.1.94.
5. Lottati M, Kolka CM, Stefanovski D, Kirkman EL, Bergman RN. Greater omentectomy improves insulin sensitivity in nonobese dogs. Obesity. 2009;17:674-80, doi: 10.1038/oby.2008.642.
6. Ballantyne GH. Peptide YY(1-36) and peptide YY(3-36): Part I. Distribution, release and actions. Obes Surg. 2006;16:651-8, doi: 10.1381/096089206776944959.
7. Bojanowska E. Physiology and pathophysiology of glucagons-like peptide-1 (GLP-1): The role of GLP-1 in the pathogenesis of diabetes mellitus, obesity, and stress. Med Sci Monit. 2005;11:RA271-RA8.
8. Ranganath LR, Beety JM, Morgan LM, Wright JW, Howland R, Marks V. Attenuated GLP-1 secretion in obesity: cause or consequence? Gut. 1996;38:916-9, doi: 10.1136/gut.38.6.916.
9. Lugari R, Dei Cas A, Ugolotti D, Finardi L, Barilli AL, Ognibene C, et al. Evidence for early impairment of glucagon-like peptide 1-induced insulin secretion in human type 2 (non insulin-dependent) diabetes. Horm Metab Res. 2002;34:150-4, doi: 10.1055/s-2002-23199.
10. Adkins Jr RB, Davies J. Gross and microscopic anatomy of the stomach and small intestine. In: Surgery of the stomach, duodenum and small bowel. Boston: Scott Jr HW and Sawyers JL. Blackwell Scientific Publications; 1987.
11. Ulshen MH, Hoyt EC, Fuller CR, Ghatei MA, Bloom SR, Lund PK. Increased ileal proglucagon expression after jejunectomy is not suppressed by inhibition of bowel growth. Dig Dis Sci. 1996;41:677-83, doi: 10.1007/BF02213122.
12. Dowling RH. Glucagon-Like Peptide-2 and Intestinal Adaptation: An Historical and Clinical Perspective. J Nutr. 2003;133:3703-7.
13. Santoro S. Is the Metabolic Syndrome a Disease of the Foregut? Yes, Excessive Foregut. Ann Surg. 2008;247:1074-5.
14. Le Roux CW, Aylwin SJ, Batterham RL, Borg CM, Coyle F, Prasad V. Gut hormone profiles following bariatric surgery favor an anorectic state, facilitate weight loss, and improve metabolic parameters. Ann Surg. 2006;243:108-14, doi: 10.1097/01.sla.0000183349.16877.84.
15. Wallace TM, Levy JC, Matthews DR. Use and abuse of HOMA modeling. Diabetes Care. 2004;27:1487-95, doi: 10.2337/diacare.27.6.1487.
16. Geloneze B, Repetto EM, Geloneze SR, Tambascia MA, Ermetice MN. The threshold value for insulin resistance (HOMA-IR) in an admixtured population IR in the Brazilian Metabolic Syndrome Study. Diabetes Res Clin Pract. 2006;72:219-20, doi: 10.1016/j.diabres.2005.10.017.
17. Buchwald H, Avidor Y, Braunwald E, Jensen MD, Pories W, Fahrbach K, et al. Bariatric surgery: a systematic review and meta-analysis. JAMA. 2004;292:1724-37, doi: 10.1001/jama.292.14.1724.
18. Rubino F, Marescaux J. Effect of duodenal-jejunal exclusion in a nonobese animal model of type 2 diabetes: a new perspective for an old disease. Ann Surg. 2004;239:1-11, doi: 10.1097/01.sla.0000102989.54824.fc.
19. Patriti A, Facchiano E, Donini A. Comments on: Effect of duodenaljejunal exclusion in a non-obese animal model of type 2 diabetes: a new perspective for an old disease. Ann Surg. 2004;240:388-9, doi: 10.1097/01.sla.0000134632.08789.df.
20. Organ CH Jr, Cegielski MM, Grabner BJ, Keig HE, Saporta JA. Jejunoileal Bypass. Long-term Results. Ann Surg. 1980;192:38-43.
21. Näslund E, Grybäck P, Hellström PM, Jacobsson H, Holst JJ, Theodorsson E, et al. Gastrointestinal hormones and gastric emptying 20 years after jejunoileal bypass for massive obesity. Int J Obes Relat Metab Disord. 1997;21:387-92, doi: 10.1038/sj.ijo.0800418.
22. Vilsbøll T, Krarup T, Sonne J, Madsbad S, Vølund A, Juul AG, et al. Incretin secretion in relation to meal size and body weight in healthy subjects and people with type 1 and type 2 diabetes mellitus. J Clin Endocrinol Metab. 2003;88:2706-13, doi: 10.1210/jc.2002-021873.
23. Irwin N, Flatt PR. Evidence for beneficial effects of compromised gastric inhibitory polypeptide action in obesity-related diabetes and possible therapeutic implications. Diabetologia. 2009;52:1724-31, doi: 10.1007/s00125-009-1422-8.
24. Nauck MA, Baller B, Meier JJ. Gastric inhibitory polypeptide and glucagon-like peptide-1 in the pathogenesis of type 2 diabetes. Diabetes. 2004;53 Suppl 3:S190-S6, doi: 10.2337/diabetes.53.suppl_3.S190.
25. Bergman RN, Van Citters GW, Mittelman SD, Dea MK, Hamilton-Wessler M, Kim SP, et al. Central role of adipocyte in the metabolic syndrome. J Investig Med. 2001;49:119-26, doi: 10.2310/6650.2001.34108.
26. Thörne A, Lönnqvist F, Apelman J, Hellers G, Arner P. A pilot study of long-term effects of a novel obesity treatment: omentectomy in connection with adjustable gastric banding. Int J Obes Relat Metab Disord. 2002;26:193-9, doi: 10.1038/sj.ijo.0801871.
27. McTernan CL, McTernan PG, Harte AL, Levick PL, Barnett AH, Kumar S. Resistin, central obesity, and type 2 diabetes. Lancet. 2002;359:46-7, doi: 10.1016/S0140-6736(02)07281-1.
28. van Hinsbergh VW, Kooistra T, Scheffer MA, Hajo van Bockel J, van Muijen GN. Characterization and fibrinolytic properties of human omental tissue mesothelial cells. Comparison with endothelial cells. Blood. 1990;75:1490-7.
29. Meier JJ, Gethmann A, Götze O, Gallwitz B, Holst JJ, Schmidt WE, et al. Glucagon-like peptide 1 abolishes the postprandial rise in triglyceride concentrations and lowers levels of non-esterified fatty acids in humans. Diabetologia. 2006;49:452-8, doi: 10.1007/s00125-005-0126-y.
30. Khosrow A, Lewis GF. Intestinal lipoprotein overproduction in insulinresistant states. Current Opinion in Lipidology. 2008; 19:221-8, doi: 10.1097/MOL.0b013e3282ffaf82.
31. Felber JP. Significance of the Randle-Mechanism in the etiology of diabetes type II. Horm Metab Res Suppl. 1990;22:11-7.
32. De Fronzo RA, Ferranini E. Insulin resistance: a multifaceted syndrome responsible for NIDDM, obesity, hypertension, dyslipidemia and atherosclerotic cardiovascular disease. Diabetes Care. 1991;14:173-94, doi: 10.2337/diacare.14.3.173.
33. Rahmouni K, Correia ML, Haynes WG, Mark AL. Obesity-associated hypertension: new insights into mechanisms. Hypertension. 2005;45:9-14, doi: 10.1161/01.HYP.0000154312.87612.07.
34. Paris M, Tourrel-Cuzin C, Plachot C, Ktorza A. Review: Pancreatic b-Cell Neogenesis Revisited. Experimental Diab Res. 2004;5:111-21, doi: 10.1080/15438600490455079.
35. Zhou J, Wang X, Pineyro MA. Glucagon-like peptide 1 and exendin-4 convert, pancreatic AR42J cells into glucagon- and insulin-producing cells. Diabetes. 1999;48:2358-66, doi: 10.2337/diabetes.48.12.2358.
36. Drucker DJ. The biology of incretin hormones. Cell Metab 2006;3:153-65, doi: 10.1016/j.cmet.2006.01.004.
37. Diabetes Control and Complications Trial (DCCT) Research Group. The effect of intensive treatment of intensive treatment of diabetes on the development and progression of long-term complications in insulindependent diabetes mellitus. N Engl J Med. 1993;329:977-86, doi: 10.1056/NEJM199309303291401.